Login / Signup

Coagulation Factor XIIIa Inhibitor Tridegin: On the Role of Disulfide Bonds for Folding, Stability, and Function.

Charlotte A BäumlThomas SchmitzAjay Abisheck Paul GeorgeMonica SudarsanamKornelia HardesTorsten SteinmetzerLori A HolleAlisa S WolbergBernd PötzschJohannes OldenburgArijit BiswasDiana Imhof
Published in: Journal of medicinal chemistry (2019)
Tridegin is a potent and specific 66mer peptide inhibitor of coagulation factor XIIIa with six cysteines involved in three disulfide bonds. Three of the 15 possible 3-disulfide-bonded isomers have been identified, which share a bridge between cysteines 19 and 25. We synthesized the three possible 2-disulfide-bonded analogues using a targeted protecting group strategy to investigate the impact of the C19-C25 bond on tridegin's folding, stability, and function. The FXIIIa inhibitory activity of the analogues was retained, which was shown by in vitro fluorogenic activity and whole blood clotting assays. Molecular dynamics simulations of wild-type tridegin and the analogues as well as molecular docking studies with FXIIIa were performed to elucidate the impact of the C19-C25 bond on conformational stability and binding mode. The strategy of selectively reducing disulfide bonds to facilitate large-scale synthesis, while retaining the functionality of disulfide-bonded peptides, has been demonstrated with our present study.
Keyphrases
  • molecular dynamics simulations
  • molecular docking
  • wild type
  • single molecule
  • cancer therapy
  • transition metal
  • high throughput
  • transcription factor
  • drug delivery
  • amino acid
  • case control
  • dna binding